Bristol-Myers Squibb’s “Overweight” Rating Reaffirmed at Barclays (BMY)
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “overweight” rating reiterated by investment analysts at Barclays in a note issued to investors on Thursday, AnalystRatings.Net reports. They currently have a $65.00 target price on the stock. Barclays’ price objective points to a potential upside of 24.71% from the company’s current price.
Bristol-Myers Squibb (NYSE:BMY) opened at 52.12 on Thursday. Bristol-Myers Squibb has a 52 week low of $41.11 and a 52 week high of $57.49. The stock’s 50-day moving average is $50.52 and its 200-day moving average is $52.20. The company has a market cap of $86.372 billion and a price-to-earnings ratio of 30.17.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.43 by $0.03. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter last year, the company posted $0.41 earnings per share. Bristol-Myers Squibb’s revenue was down .5% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb will post $1.79 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. They now have a $59.00 price target on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. They now have a $62.00 price target on the stock. Finally, analysts at William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $56.15.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.